Should I buy or sell Cyclo Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cyclo Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CYTH shares. View CYTH analyst ratings or view top-rated stocks .

What is Cyclo Therapeutics' stock price target for 2024?

1 Wall Street analysts have issued 1-year target prices for Cyclo Therapeutics' stock. Their CYTH share price targets range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 198.5% from the stock's current price. View analysts price targets for CYTH or view top-rated stocks among Wall Street analysts .

How have CYTH shares performed in 2023?

Cyclo Therapeutics' stock was trading at $1.42 on January 1st, 2023. Since then, CYTH shares have decreased by 5.6% and is now trading at $1.34. View the best growth stocks for 2023 here .

Are investors shorting Cyclo Therapeutics?

Cyclo Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 223,000 shares, an increase of 76.4% from the October 31st total of 126,400 shares. Based on an average daily volume of 55,400 shares, the short-interest ratio is currently 4.0 days. Approximately 2.6% of the company's stock are short sold. View Cyclo Therapeutics' Short Interest .

When is Cyclo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 18th 2024. View our CYTH earnings forecast .

How were Cyclo Therapeutics' earnings last quarter?

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) announced its earnings results on Friday, March, 17th. The company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.34. The business earned $0.19 million during the quarter. Cyclo Therapeutics had a negative trailing twelve-month return on equity of 1,706.53% and a negative net margin of 2,037.29%.

How do I buy shares of Cyclo Therapeutics?

Shares of CYTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Cyclo Therapeutics Stock Price, News & Analysis (NASDAQ:CYTH)

$1.32

+0.01 (+0.76%)

(As of 05:28 PM ET)

Compare

Today's Range: $1.29
▼
$1.49
50-Day Range: $0.93
▼
$1.69
52-Week Range: $0.67
▼
$2.57

Volume: 38,195 shs
Average Volume: 92,995 shs
Market Capitalization: $30.01 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Cyclo Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 198.5% Upside
$4.00 Price Target
Short Interest: Bearish
2.57% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

756th out of 958 stocks

Biological Products, Except Diagnostic Industry

113th out of 143 stocks

3.5

Analyst's Opinion

Consensus Rating
Cyclo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.00, Cyclo Therapeutics has a forecasted upside of 198.5% from its current price of $1.34.
Amount of Analyst Coverage
Cyclo Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.57% of the float of Cyclo Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Cyclo Therapeutics has a short interest ratio ("days to cover") of 4.
Change versus previous month
Short interest in Cyclo Therapeutics has recently increased by 76.42%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Cyclo Therapeutics does not currently pay a dividend.
Dividend Growth
Cyclo Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CYTH.

2.7

News and Social Media Coverage

News Sentiment
Cyclo Therapeutics has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
Search Interest
Only 1 people have searched for CYTH on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
MarketBeat Follows
3 people have added Cyclo Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cyclo Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
29.78% of the stock of Cyclo Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 23.03% of the stock of Cyclo Therapeutics is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Cyclo Therapeutics is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cyclo Therapeutics is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cyclo Therapeutics has a P/B Ratio of 19.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cyclo Therapeutics Stock (NASDAQ:CYTH)

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of neurodegenerative diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo that is in Phase IIb clinical trials for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.

CYTH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CYTH Stock News Headlines

November 29, 2023 | businesswire.com

APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied ...

November 21, 2023 | finance.yahoo.com

Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024

December 7, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 15, 2023 | msn.com

Cyclo Therapeutics reports Q3 results

November 15, 2023 | finance.yahoo.com

Cyclo Therapeutics Reports Third Quarter 2023 Financial Results

November 10, 2023 | seekingalpha.com

WISH, REAL and PIXY among mid-day movers

November 2, 2023 | finance.yahoo.com

Several Insiders Invested In Cyclo Therapeutics Flagging Positive News

October 30, 2023 | finance.yahoo.com

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results

December 7, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

October 23, 2023 | finance.yahoo.com

Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million

October 5, 2023 | finance.yahoo.com

Cyclo Therapeutics to Present at 8th Annual Dawson James Conference

September 21, 2023 | tmcnet.com

CYTH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cyclo Therapeutics, Inc. Is Fair to Shareholders

September 21, 2023 | finance.yahoo.com

Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement

August 15, 2023 | finance.yahoo.com

Cyclo Therapeutics Reports Second Quarter 2023 Financial Results

August 3, 2023 | benzinga.com

Cyclo Therapeutics And This Other Penny Stock Insiders Are Buying

June 12, 2023 | benzinga.com

Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol® Cyclo™ for Alzheimer's Disease

May 22, 2023 | finance.yahoo.com

Positive Signs As Multiple Insiders Buy Cyclo Therapeutics Stock

May 15, 2023 | finance.yahoo.com

Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

May 2, 2023 | finance.yahoo.com

Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

April 28, 2023 | benzinga.com

Cyclo Therapeutics Stock (NASDAQ:CYTH), Guidance and Forecast

April 21, 2023 | finance.yahoo.com

Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules

March 21, 2023 | msn.com

Cyclo Therapeutics's Return On Capital Employed Insights

March 20, 2023 | marketwatch.com

Cyclo Therapeutics in Talks About Possible Combination

March 20, 2023 | finance.yahoo.com

Cyclo Therapeutics Provides Business Update and Reports Full Year 2022 Financial Results

March 15, 2023 | seekingalpha.com

CYTH Cyclo Therapeutics, Inc.

March 10, 2023 | benzinga.com

Cyclo Therapeutics Chief Operating Officer Awarded $44K Worth of Stock Options

March 10, 2023 | benzinga.com

Cyclo Therapeutics Chief Regulatory Officer Awarded $44K Worth of Stock Options

See More Headlines

Receive CYTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/17/2023
Today: 12/07/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CYTH
CUSIP: N/A
CIK: 922247
Web: www.ctd-holdings.com
Phone: (386) 418-8060
Fax: 321-244-8351
Employees: 9
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.00
High Stock Price Target: $4.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +198.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.67)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-15,450,000.00
Net Margins: -2,037.29%
Pretax Margin: -2,037.19%
Return on Equity: -1,706.53%
Return on Assets: -418.15%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.83
Quick Ratio: 0.80

Sales & Book Value

Annual Sales: $951,809.00
Price / Sales: 32.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.07 per share
Price / Book: 19.14

Miscellaneous

Outstanding Shares: 22,732,000
Free Float: 15,962,000
Market Cap: $30.46 million
Optionable: Not Optionable
Beta: -0.04

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. N. Scott Fine (Age 66)
CEO & Director
Comp: $877.88k
Mr. C. E Strattan (Age 77)
Founder & Director
Comp: $44k
Mr. Joshua M. Fine (Age 41)
CFO & Secretary
Comp: $509.38k
Mr. Michael Eric Lisjak (Age 50)
Chief Regulatory Officer & Senior VP of Business Development
Comp: $505.9k
Dr. Jeffrey L. Tate Ph.D. (Age 65)
COO, Chief Quality Officer & Director
Comp: $255.14k
Ms. Lori McKenna Gorski
Global Head of Patient Advocacy
Dr. Karen Mullen FFPM
Interim Chief Medical Officer

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

CYTH Stock Analysis - Frequently Asked Questions

Should I buy or sell Cyclo Therapeutics stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cyclo Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CYTH shares.
View CYTH analyst ratings or view top-rated stocks.
What is Cyclo Therapeutics' stock price target for 2024?: 1 Wall Street analysts have issued 1-year target prices for Cyclo Therapeutics' stock. Their CYTH share price targets range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 198.5% from the stock's current price.
View analysts price targets for CYTH or view top-rated stocks among Wall Street analysts.
How have CYTH shares performed in 2023?: Cyclo Therapeutics' stock was trading at $1.42 on January 1st, 2023. Since then, CYTH shares have decreased by 5.6% and is now trading at $1.34.
View the best growth stocks for 2023 here.
Are investors shorting Cyclo Therapeutics?: Cyclo Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 223,000 shares, an increase of 76.4% from the October 31st total of 126,400 shares. Based on an average daily volume of 55,400 shares, the short-interest ratio is currently 4.0 days. Approximately 2.6% of the company's stock are short sold.
View Cyclo Therapeutics' Short Interest.

When is Cyclo Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 18th 2024.
View our CYTH earnings forecast.
How were Cyclo Therapeutics' earnings last quarter?: Cyclo Therapeutics, Inc. (NASDAQ:CYTH) announced its earnings results on Friday, March, 17th. The company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.34. The business earned $0.19 million during the quarter. Cyclo Therapeutics had a negative trailing twelve-month return on equity of 1,706.53% and a negative net margin of 2,037.29%.
How do I buy shares of Cyclo Therapeutics?: Shares of CYTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CYTH) was last updated on 12/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial